In a review of the literature published in The Cochrane Library, two Israeli authors conclude that the use of topical corticosteroid nasal sprays-either alone or in combination with antibiotic therapy-shows an advantage over placebo in the treatment of the symptoms of acute rhinosinusitis.
Affecting more than 30 million Americans, chronic rhinosinusitis (CRS) has been a frustrating disease with no long-lasting results from traditional steroidal and antibiotic treatment, or from surgery. With both clinicians and patients desperate for a solution, it is not surprising that hope-and controversy-has arisen over a potential new therapy.
Rhinitis—inflammation of the nasal mucosa—has two main types: allergic (IgE-mediated) and nonallergic; together, they affect more than 50 million Americans.
Dysphagia is the dominant cause of morbidity and mortality in patients treated by otolaryngologists, and in fact, more people die from aspiration pneumonia following stroke than from all head and neck cancers combined.
There are few data to support primary surgical reduction of the inferior turbinates in the pediatric patient.
Although little prospective data exist evaluating surgical turbinate reduction for chronic pediatric sinusitis and rhinitis, some otolaryngologists do perform the procedure on patients for whom medical therapy has been aggressively tried but clinical symptoms persist.
At its annual meeting, the American Academy of Otolaryngology-Head and Neck Surgery released its long-awaited multispecialty practice guidelines for treatment of adult rhinosinusitis.
Michael S. Morris, MD, believes that the everyday illnesses seen by community otolaryngologists should be better analyzed. Is it an allergy or an infection? Is it a bug? We should find out, he said.